Inhibition of human UDP‐glucuronosyltransferase enzyme by Dabrafenib: Implications for drug–drug interactions

Dabrafenib is a novel small molecule tyrosine kinase inhibitor (TKI) which is used to treat metastatic melanoma. The aim of this research was to survey the effects of dabrafenib on human UDP‐glucuronosyltransferases (UGTs) and to evaluate the risk of drug–drug interactions (DDIs). The formation rates for 4‐methylumbelliferone (4‐MU) glucuronide and trifluoperazine‐glucuronide in 12 recombinant human UGT isoforms with or without dabrafenib were...